Consensus CalciMedica, Inc.

Equities

CALC

US38942Q2021

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-12 pm EDT			5-day change	1st Jan Change
5.2 ^USD	-7.14%		-5.80%	+81.81%

May. 13	CalciMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis	CI

Evolution of the average Target Price on CalciMedica, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b34bd9d68e3c1d5859a06795a9fb9.vCoE9RoeFTFywdaQHSYTH5IWr1tIRWK2bAkC3rcqgGA.3hJ1lndUeVggg7jYd2x7ZuFD2j0GPRrgKWJTn81MsBWJQ1y8fmZUSEqI7g~e42ccf8e556fdc8316806462bab82a7f

Analyst Recommendations on CalciMedica, Inc.

JonesTrading Initiates CalciMedica With Buy Rating, Price Target is $22	Feb. 16	MT
HC Wainwright Starts Coverage on CalciMedica with Buy Rating, $20 Price Target	Jan. 29	MT
EF Hutton Initiates CalciMedica With Buy Rating, $17 Price Target	23-06-20	MT
Wedbush Drops Coverage of Graybug Vision on Termination of GB-102 for Wet Age-Related Macular Degeneration, GB-401 for Primary Open-Angle Glaucoma	22-08-26	MT
Piper Sandler Adjusts Graybug Vision's Price Target to $2 From $4, Maintains Neutral Rating	22-05-19	MT
Cantor Fitzgerald Adjusts Graybug Vision Price Target to $4 From $6, Maintains Overweight Rating	22-03-10	MT
Wedbush Analyst Starts Graybug Vision at Neutral With $3 Price Target, Down From $4	21-12-15	MT
GRAYBUG VISION : Wedbush Adjusts Price Target on Graybug Vision to $4 From $8 on GB-102 Timeline Adjustments; Neutral Rating Kept	21-05-13	MT
GRAYBUG VISION : Cantor Fitzgerald Adjusts Price Target for Graybug Vision to $6 From $14, Maintains Overweight Rating	21-05-13	MT
GRAYBUG VISION : SVB Leerink Downgrades Graybug Vision to Market Perform From Outperform, Adjusts PT to $5 From $23	21-05-13	MT
GRAYBUG VISION : Needham Downgrades Graybug Vision to Hold from Buy	21-05-13	MT
GRAYBUG VISION : Wedbush Downgrades Graybug Vision to Neutral From Outperform on Mixed Results of Phase 2b Altissimo Study	21-03-09	MT
GRAYBUG VISION : SVB Leerink Adjusts Graybug Vision's Price Target to $23 from $45, Keeps Outperform Rating	21-03-09	MT
GRAYBUG VISION : Piper Sandler Downgrades Graybug Vision to Neutral From Overweight; Price Target is $10	21-03-09	MT
GRAYBUG VISION : Cantor Fitzgerald Starts Graybug Vision at Overweight With $42 Price Target	20-12-22	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.55 USD

Average target price

18.67 USD

Spread / Average Target

+236.34%

High Price Target

22 USD

Spread / Highest target

+296.40%

Low Price Target

14 USD

Spread / Lowest Target

+152.25%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CalciMedica, Inc.

JonesTrading Institutional Services
HC Wainwright
EF Hutton
Wedbush
Piper Sandler
Cantor Fitzgerald
Needham & Co.
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar